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Abstract: 
 
Background: Real-time continuous glucose monitoring is associated with 
significant benefits for diabetes management. Implantable sensors could 
overcome some challenges reportedly associated with device visibility, 
psychosocial functioning and sensor durability. 
 
Methods: A psychosocial assessment was conducted to determine 
acceptability and impact of an implantable continuous glucose monitoring 
(CGM) sensor as part of the PRECISE trial. Questionnaires were 
administered to participants comprising the diabetes distress scale, the CGM 
impact scale and bespoke device satisfaction.  
 
Results: Fifty-one participants across UK (n=10) and Germany (n=41) 
completed the questionnaires. Of these, 90% had T1D, 50% followed an 
insulin pump therapy regimen, and 45% of the participants were previous 
CGM users. CGM Impact Scale results show 86% (n=44) of participants 
reported feeling better (14% neutral) about their diabetes control with 90% 
CGM naïve participants and 81% previous CGM users reporting increased 
confidence about their diabetes management. Furthermore, 73% (n=37) felt 
more safe (27% neutral) while sleeping and 78% (n=39) more confident (22% 
neutral) about avoiding serious hypoglycemia. Responses correspond with an 
average improvement in HbA1c from 7.51 to 7.05 (p<.0001) over the 90 days 
use of the CGM. Overall, the system was rated highly on ease of use, 
convenience and comfort. 84% would choose to be inserted again with 93% 
of CGM naïve participants (86% previous CGM users) reporting minimized 
burden of diabetes.  
 
Conclusions: Implantable CGM devices are acceptable to users and are 
evaluated favourably. The considerable majority of participants (93% of first 
time users and 77% previous CGM users) would like to continue using the 
system to help manage their diabetes more effectively. 
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Acceptability of Implantable Continuous Glucose Monitor Sensor  
 
 
 
Background: 
An important technical innovation for type 1 diabetes has been the 
introduction of real time systems providing information on glucose trajectories 
and trends for users to improve their diabetes self-management decisions. 
CGM has been shown to be clinically effective and to enhance psychosocial 
outcomes such as increased confidence in diabetes self-management [1]. 
Inter-individual variability is substantial however with some users not realizing 
such benefits [2]. In particular, benefits seem to depend on duration of use, 
and in some groups with low usage, there have been limited benefits [3]  
 
Downsides to the technology have focused on poor reliability, alarm fatigue, 
frequent changes of sensors (typically every 6-7 days), increased burden 
associated with diabetes self-management and visibility of disease state with 
the need for additional sensors/transmitter and receiving device [4,5]. A 
recently introduced implantable sensor with a duration of three to six months 
with connectivity through smartphone technology may address issues of 
regular usage, longevity and to some extent visibility of disease state.  
 
The aim of the current study was to explore the psychosocial outcomes 
associated with wearing an implantable CGM for six months. Key issues 
include impact of device on perceptions of diabetes self-management and 
diabetes control; usability; safety; social relationships and fear of 
hypoglycemia. 
 
Methods: 
A psychosocial sub-study was conducted as part of the PRECISE trial, a 180-
day prospective multicenter pivotal trial [6]. Participants aged 18 years or 
older with type 1 or type 2 diabetes were implanted with the implantable 
Eversense (Senseonics Inc) CGM sensor.  The sensor was placed in 
participants’ upper arm with the removable transmitter positioned on the skin 
over the sensor. Quantitative psychosocial assessments were administered at 
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ninety days to participants to explore patient reported outcomes associated 
with an implantable CGM sensor. The questionnaire comprised the Diabetes 
Distress Scale (DDS)[7], a twenty-eight item scale which assesses worries 
and concerns specifically related to diabetes and its management; it has been 
shown to be a good marker of factors important to diabetes-related Quality of 
Life (QoL). Responses are rated on a 6-point scale from ‘not a problem’ to ‘a 
very serious problem’; the CGM Impact Scale [8] which is a sixteen item scale 
assessing experiences with CGM and designed to measure the impact of 
CGM on diabetes management and family relationships, plus on satisfaction 
with emotional, behavioral and cognitive effects of CGM use. Responses are 
rated on a 5-point scale from ‘much better’ to ‘much worse’; and thirty-three 
bespoke device satisfaction questions, which were developed by a multi-
disciplinary team for this study to assess acceptability of the device. 
Questions were both open-ended and likeart scale response (range 1-7, 
strongly agree to disagree) focusing on participant experience of using the 
CGM, its features, functionality and usability.  The questionnaire bank was 
piloted with potential participants prior to use and minor revisions made.   
 
Quantitative analysis was conducted using SPSS v.21 and free text 
responses were analyzed using content and thematic methodology. Two 
researchers independently reviewed all free text responses, and consensus of 
key themesreached. 
 
Results: 
Fifty-one participants took part in the study across the UK (n=10) and 
Germany (n=41). Of these, forty-six had T1D, five had T2D. Participants were 
similarly split between multiple daily injections (MDI) (n=25) and insulin pump 
therapy regimen (n=26). Similarly, 55% of participants were first time users of 
CGM (n=28), 45% were current or previous CGM users 
 
Table 1 shows the frequency of which participants looked at the glucose 
display on their iPod, subdivided by mode of therapy and first vs. previous 
CGM users. Recommended daily checking frequency of blood glucose is 
around four times a day, however the ability to easily see the reading without 
having to perform a finger prick check is commonly associated with greater 
 5 
frequency of checking. This was reflected in the current study where all 
participants reporting having viewed their CGM data more frequently than 
they had done so prior to enrolling in the study. 
 
Insert table one about here 
 
 
CGM impact scale data shows that participants report improvements in terms 
of confidence over their diabetes control (85%), blood glucose levels (60%) 
and optimism about avoiding long-term complications (78%). Furthermore, 
participants reported feeling safer when sleeping (72%), more confident about 
avoiding severe hypoglycemia (76%) and more motivated to keep up with 
their diabetes management (80%) (see Table 2). 
 
Overall, the system was rated highly on ease of use, convenience and 
comfort with 92% indicated that they did not experience pain or discomfort 
when using the sensor. 84% would choose to be inserted again with 93% of 
CGM naïve participants (86% previous users) reporting minimized burden of 
diabetes. Previous CGM users reported better sensor comfort (82% vs 71%) 
and were more likely to use the sensor for every day management than naïve 
users (93% vs 77%). 
 
Insert table two about here 
 
Participants reported improvements on all domains of the diabetes distress 
scale, i.e. emotional burden, physician-related distress, regime-related 
distress and interpersonal distress (see Table 3). Furthermore, 72% (n=36) 
judged the CGM to be very helpful in managing their diabetes more easily 
(score 8-10) on a scale of 1-10, 18% (n=9) scored 4-7 an 8% scored 1-3 not 
very helpful. 
 
Insert table three about here 
 
 
Free text responses identified key themes in terms of what participants 
particularly liked about the device, what they particularly disliked, experiences 
with CGM alarms, challenges using the device and overall impressions. The 
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main benefit reported was visibility of trends and data (n=33) with key dislike 
reported as technical difficulties such as alarms, connectivity and frequency of 
charging (n=23). Specifically relating to alarms, there were mixed responses 
with 56% (n=28) of participants reporting positive experience, however 20% 
(n=10) preferred the ability to customize the alarms with 22% (n=11) finding 
them too sensitive or too quiet at night. The most common occasions when 
participants chose not to wear the transmitter were when 
bathing/showering/swimming (98%, n=49) followed by recharging (20%, 
n=10). Participants were informed that the transmitter was not water tight. 
Furthermore, it had to be charged once daily, which could be done within 15 
minutes, e.g. during bathing. Overall, the majority of participants were 
impressed with the system stating ease of use of making life easier (n=41). 
 
Discussion: 
Here we report that fifty-one participants who took part in the PRECISE study 
across the UK and Germany reported positive psychosocial outcomes while 
using an implantable continuous glucose monitor. 
 
Most studies show that users receive verifiable benefit when they use CGM 
intensively, i.e. every day [2,6]. In practice, however up to 40% of those who 
use sensors discontinue use over the course of a year [9]. Even in clinical 
studies, sensor usage has often been below 60% in some groups [2]. There 
are a number of reasons for this: the cost of sensors is unaffordable for many; 
inaccurate measurement and interpretation of glucose information occurs; 
alarm fatigue; pain, irritation at the site of the sensor,[9] negative reactions 
from the social environment e.g. needing to justify why a technical device is 
being constantly worn or to explain an alarm; the overload of data and 
feelings of being overwhelmed by information. An implantable sensor may 
address some of these issues.  Participants specifically cite the longevity of 
the device as a benefit, removing the need for frequent sensor replacements.  
The low visibility of the sensor device removes the visible appearance of the 
technology and the use of a mobile device is commonplace so avoids drawing 
attention to a piece of ‘medical’ equipment lowering the visibility of disease 
state. 
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Often, participants feel frustrated that their expectations of CGM technology 
are not met. Exploring expectations prior to use and revisiting these 
periodically may help to address this. Helping people to learn how to process 
the additional data provided by CGM and managing expectations around the 
amount of time and effort required to master the system to best meet 
individual needs is important to support optimal use. Furthermore, user 
friendliness of CGM devices has been reported as an area requiring 
improvement [10].  
 
Patient reported outcome data reported here is comparable for CGM users 
and non-CGM users with T1D in the literature [10]; something that is 
reinforced in the current study with no deterioration associated with 
implantable CGM use. Interestingly, significantly greater benefit for 
convenience, acceptability of BG monitoring requirements, BG control 
efficacy, diabetes worries and interpersonal hassles associated with CGM and 
CSII use is reported [9], however participants were naïve to pump therapy as 
well as CGM and it is not possible to separate the impact in terms of device. 
All of the benefits are commonly reported as associated with insulin pump 
therapy, so it could be argued that the benefit in insulin therapy 
overshadowed CGM impact on these psychosocial outcomes.   
 
Engagement with CGM usage is positively associated with improvements in 
glycemic control [10] and results from the current study show that the majority 
participants were routinely checking the screen to see their BG values 
frequently (table 1) during the trial. The ability to easily see the number and 
trend direction of BG travel has been widely positively reported as reassuring 
in closed loop research [5] and this was cited by 66% of participants as a 
particular benefit in the current study. The reduced burden of technology in 
terms of ease of use, ease to learn, ability to wear in everyday settings, 
convenience and comfort reported by participants addresses the needs of 
people with diabetes reported in the literature [11]. 
 
Strengths of the study include rigorous psychosocial assessment alongside 
medical outcomes in the main PRECISE trial including both quantitative and 
free text response options to explore potential facilitators and barriers to 
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sustained use of the device. Limitations of the current study include the 
relatively small sample size (n=51) however this is a pilot study and further 
research is ongoing.  Further, the lack of baseline psychosocial data makes it 
difficult to draw definite conclusions, however the consistency across three 
and six-month follow-up reflects durable impact on such factors important to 
quality of life of participants. 
 
In conclusion, an implantable CGM sensor was acceptable to participants and 
use of the system was associated with minimized burden of diabetes. 
Psychosocial functioning and factors important to quality of life were reported 
as positively associated with the device by users. 
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Table One: Frequency of BG ‘Checking’ on iPod 
 Therapy CGM Use 
Frequency CSII 
(n=25) 
MDI 
(n=25) 
1st 
(28) 
Repeat 
(n=22) 
Every 
 Hour or > 
18 18 21 15 
every 2 
hours 
4 5 5 4 
Approx. 6 
times daily 
3 2 2 3 
CSII – Insulin Pump User, MDI: Multiple daily injections 
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Table Two:  CGM Impact Scale at Three Months Follow-up 
  Mean Response (SD) 
  Therapy CGM Use 
Item All Users CSII     
(n= 25) 
MDI  
(n= 25) 
1st (n=28) Repeat 
(n=22) 
Do you now feel more confident or less 
confident that you can control your 
diabetes? 
1.51 (0.74) 1.56 (0.77)  1.36 (0.64) 1.39 (0.69) 1.61 (0.78) 
Do you now feel more or less in control or 
less in control of your life and your 
diabetes? 
1.86 (0.87) 2.04 (0.98) 1.56 (0.65) 1.79 (0.96) 1.87 (0.76) 
Do you now feel more hopeful or less 
hopeful that you can avoid long-term 
complications? 
1.87 (0.76) 2.12 (0.73) 1.56 (0.71) 1.75 (0.75) 1.96 (0.77) 
Do you now feel more motivated or less 
motivated to keep up with your diabetes 
management? 
1.80 (0.82) 1.84 (0.75) 1.72 (0.89) 1.79 (0.83) 1.78 (0.80) 
Is it now harder or is it easier to adjust your 
insulin doses correctly? 
1.96 (0.82) 1.88 (0.78) 1.92 (0.86) 1.89 (0.83) 1.96 (0.82) 
Have your blood glucoses become more or 
become less of a “roller coaster”? 
2.16 (0.85) 2.36 (0.81) 1.92 (0.81) 2.14 (0.71) 2.17 (0.98) 
Has your A1C improved or has it worsened? 2.25 (0.75) 2.42 (0.58) 2.00 (0.86) 2.13 (0.80) 2.38 (0.67) 
Do you now feel more free or less free to do 
the things in your life you really want to do? 
2.24 (0.92) 2.48 (0.77) 1.92 (1.00) 2.14 (0.97) 2.30 (0.88) 
Do you now feel more safe or less safe when 
exercising? 
2.04 (0.91) 2.04 (0.79) 2.00 (1.04) 2.04 (1.00) 2.04 (0.82) 
Do you now feel more safe or less safe 
about sleeping? 
1.84 (0.85) 1.96 (0.84) 1.64 (0.86) 1.68 (0.86) 1.96 (0.82) 
Do you now feel more fearful or less fearful 
about hypoglycemia? 
2.08 (0.98) 2.12 (0.97) 1.92 (1.00) 2.00 (1.09) 2.09 (0.85) 
Do you now feel more confident or less 
confident that you can avoid serious 
hypoglycemia? 
1.73 (0.84) 1.68 (0.80) 1.68 (0.85) 1.57 (0.74) 1.87 (0.92) 
 Do you now feel more safe or less safe 
while driving? 
2.08 (0.93) 2.04 (0.93) 2.04 (0.93) 1.93 (0.94) 2.22 (0.90) 
Are your relationships with your family and 
friends now better or worse? 
2.78 (0.59) 2.92 (0.40) 2.64 (0.70) 2.79 (0.57) 2.78 (0.60) 
Is your partner now worrying less or 
worrying more about sleeping at night? 
2.33 (0.85) 2.52 (0.77) 2.12 (0.88) 2.32 (0.86) 2.35 (0.83) 
Are your friends and family now bothering 
you less or bothering you more about your 
diabetes? 
2.53 (0.77) 2.72 (0.61)  2.36 (0.86) 2.61 (0.74) 2.48 (0.79) 
Scale:  1=much better; 2=slightly better; 3=neutral; 4=slightly worse; 5=much worse 
 
 
 
 
 
 
 
 
 
 
 12 
Table Three:  Diabetes Distress Scale – All Items at Three Month Follow-up 
 Mean Response (SD) 
  Therapy CGM Use 
Item All Users CSII  
(n=25) 
MDI  
(n=25) 
1st   
(n=28)  
Repeat 
(n=22) 
Feeling overwhelmed by the 
demands of living with diabetes. 1.88 (0.85) 1.96 (0.84) 1.76 (0.83) 1.75 (0.70) 2.04 (0.98) 
Feeling that I am often failing with 
my diabetes routine. 
2.00 (1.11) 2.2 (1.15) 1.68 (0.80) 1.61 (0.69)  2.48 (1.31) 
 Feeling that diabetes is taking up too 
much of my mental and physical 
energy every day. 
1.54 (0.71) 1.56 (0.65) 1.52 (0.77) 1.39 (0.63) 1.78 (0.80) 
Feeling that my doctor doesn't know 
enough about diabetes and diabetes 
care. 
1.20 (0.57) 1.12 (0.33) 1.36 (0.81) 1.32 (0.72) 1.13 (0.46) 
Feeling angry, scared, and/or 
depressed when I think about living 
with diabetes. 
1.46 (0.68) 1.48 (0.65) 1.44 (0.71) 1.39 (0.57) 1.57 (0.79) 
Feeling that my doctor doesn't give 
me clear enough directions on how 
to manage my diabetes. 
1.20 (0.49) 1.2 (0.41) 1.20 (0.58) 1.14 (0.52) 1.26 (0.45) 
Feeling that I am not testing my 
blood sugars frequently enough. 
1.58 (0.99) 1.8 (1.26) 1.36 (0.57) 1.36 (0.56)  1.83 (1.30) 
Feeling that I am often failing with 
my diabetes routine. 
1.96 (1.01) 2.12 (1.09) 1.68 (0.63) 1.64 (0.68) 2.35 (1.19) 
Feeling that friends or family are not 
supportive enough of self-care 
efforts (e.g. planning activities that 
conflict with my schedule, 
encouraging me to eat the "wrong" 
foods). 
1.42 (0.76) 1.64 (0.95) 1.20 (0.41) 1.32(0.55) 1.52 (0.95) 
Feeling that diabetes controls my 
life. 
1.94 (1.04) 1.84 (0.75) 1.92 (1.12) 1.79 (0.88) 2.13 (1.18) 
Feeling that my doctor doesn't take 
my concerns seriously enough. 
1.14 (0.35) 1.17 (0.38) 1.12 (0.33) 1.11 (0.32) 1.17 (0.39) 
 Not feeling confident in my day-to-
day ability to manage diabetes. 
1.43 (0.71) 1.38 (0.49) 1.40 (0.71) 1.22 (0.42) 1.70 (0.88) 
Feeling that I will end up with serious 
long-term complications, no matter 
what I do. 
2.24 (1.30) 2.54 (1.53) 1.96 (0.98) 2.00 (1.21) 2.52 (1.34) 
Feeling that I am not sticking closely 
enough to a good meal plan. 
2.12 (1.25) 2.25 (1.39) 1.92 (0.95) 1.85 (0.91) 2.48 (1.50) 
Feeling that friends or family don't 
appreciate how difficult living with 
diabetes can be. 
2.02 (1.18) 2.25 (1.33) 1.76 (0.93) 1.67 (0.88) 2.48 (1.34)  
Feeling overwhelmed by the 
demands of living with diabetes. 
1.57 (0.79) 1.63 (0.65) 1.44 (0.77) 1.37 (0.63) 1.83 (0.89) 
Feeling that I don't have a doctor 
who I can see regularly enough 
about my diabetes. 
1.14 (0.46) 1.08 (0.28) 1.2 (0.58) 1.19 (0.56) 1.09 (0.29) 
Not feeling motivated to keep up my 
diabetes self management. 
1.49 (0.77) 1.58 (0.65) 1.36 (0.86) 1.22 (0.42) 1.78 (0.95) 
Feeling that friends or family don't 
give me the emotional support that I 
would like. 
1.43 (0.84) 1.58 (1.06) 1.32 (0.56) 1.19 (0.40) 1.74 (1.10) 
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